HomeCrosponCrospon Receives 510(k) FDA Clearance for Endoflip® with Flip® Topography Module

Crospon Receives 510(k) FDA Clearance for Endoflip® with Flip® Topography Module

Company reports that the new Endoflip® System Will Greatly Improve the Quality of Patient Experience During Swallow Testing

Crospon, an endoscopic diagnostics company, today announced it has received US Food and Drug Administration (FDA) 510(k) clearance for its Endoflip® System with Flip® Topography Module, providing a new way for clinicians to assess patient motility disorders during endoscopy.

Continuing Crospon’s commitment to deliver information into the hands of gastroenterologists, the next generation of the Endoflip® System, Endoflip® 2.0, introduces imaging software that displays real-time esophageal contractility patterns on a 24” touch-screen. The unique repetitive visual cues of the patented Endoflip® technology enables gastroenterologists, for the first time, to investigate for conditions such as achalasia, GEJ outflow obstruction and other major or minor disorders of peristalsis during endoscopy. EndoFLIP 2.0 also introduces the new capability to capture and store Endoflip® images in electronic patient records.

John O’Dea, CEO and Founder of Crospon highlights, “This clearance represents a significant milestone for our organisation as we can now offer physicians an additional tool that can be used during endoscopy, along with other diagnostic methods, to evaluate patients with symptoms consistent with gastrointestinal motility disorders.”

O’Dea concluded, “The stand out benefit of this application, for both patients and caregivers, is that the Flip® Topography assessment can be performed in less than five minutes during upper endoscopy on a sedated patient. In addition to significantly reducing discomfort, the patient may not have to wait for testing at a specialised center, thereby reducing their time to treatment. While not always a substitute for manometry, Endoflip® 2.0 can reveal situations of non-obstructive dysphagia which may benefit from further evaluation from manometry.”

The company notes that shipments of Endoflip® 2.0 systems will commence in June 2017.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy